PMID- 31212865
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Electronic)
IS  - 2075-4418 (Linking)
VI  - 9
IP  - 2
DP  - 2019 Jun 12
TI  - Expressions of HLA Class II Genes in Cutaneous Melanoma Were Associated with 
      Clinical Outcome: Bioinformatics Approaches and Systematic Analysis of Public 
      Microarray and RNA-Seq Datasets.
LID - 10.3390/diagnostics9020059 [doi]
LID - 59
AB  - Major histocompatibility complex (MHC) class II molecules, encoded by human 
      leukocyte antigen (HLA) class II genes, play important roles in antigen 
      presentation and initiation of immune responses. However, the correlation between 
      HLA class II gene expression level and patient survival and disease progression 
      in cutaneous melanoma is still under investigation. In the present study, we 
      analyzed microarray and RNA-Seq data of cutaneous melanoma from The Cancer Genome 
      Atlas (TCGA) using different bioinformatics tools. Survival analysis revealed 
      higher expression level of HLA class II genes in cutaneous melanoma, especially 
      HLA-DP and -DR, was significantly associated with better overall survival. 
      Furthermore, the expressions of HLA class II genes were most closely associated 
      with survival in cutaneous melanoma as compared with other cancer types. The 
      expression of HLA class II co-expressed genes, which were found to associate with 
      antigen processing, immune response, and inflammatory response, was also 
      positively associated with overall survival in cutaneous melanoma. Therefore, the 
      results indicated that increased HLA class II expression may contribute to 
      enhanced anti-tumor immunity and related inflammatory response via presenting 
      tumor antigens to the immune system. The expression pattern of HLA class II genes 
      may serve as a prognostic biomarker and therapeutic targets in cutaneous 
      melanoma.
FAU - Chen, Yang-Yi
AU  - Chen YY
AUID- ORCID: 0000-0002-8488-635X
AD  - Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical 
      University, Kaohsiung 807, Taiwan. 1050556@kmuh.org.tw.
AD  - Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung 807, 
      Taiwan. 1050556@kmuh.org.tw.
FAU - Chang, Wei-An
AU  - Chang WA
AD  - Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical 
      University, Kaohsiung 807, Taiwan. 960215kmuh@gmail.com.
AD  - Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University 
      Hospital, Kaohsiung 807, Taiwan. 960215kmuh@gmail.com.
FAU - Lin, En-Shyh
AU  - Lin ES
AD  - Department of Beauty Science, National Taichung University of Science and 
      Technology, Taichung 403, Taiwan. eslin7620@gmail.com.
FAU - Chen, Yi-Jen
AU  - Chen YJ
AD  - Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical 
      University, Kaohsiung 807, Taiwan. chernkmu@gmail.com.
AD  - Department of Physical Medicine and Rehabilitation, Kaohsiung Medical University 
      Hospital, Kaohsiung 807, Taiwan. chernkmu@gmail.com.
FAU - Kuo, Po-Lin
AU  - Kuo PL
AUID- ORCID: 0000-0003-2487-2818
AD  - Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical 
      University, Kaohsiung 807, Taiwan. kuopolin@seed.net.tw.
AD  - Institute of Medical Science and Technology, National Sun Yat-Sen University, 
      Kaohsiung 804, Taiwan. kuopolin@seed.net.tw.
LA  - eng
GR  - MOST 107-2320-B-037-011-MY3/Ministry of Science and Technology, Taiwan/
GR  - MOST107-2622-E-025-002-CC3/Ministry of Science and Technology, Taiwan/
GR  - KMU-DK 108003/Kaohsiung Medical University/
PT  - Journal Article
DEP - 20190612
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC6628136
OTO - NOTNLM
OT  - HLA class II
OT  - MHC class II
OT  - bioinformatics
OT  - cutaneous melanoma
COIS- The authors declare no conflict of interest.
EDAT- 2019/06/20 06:00
MHDA- 2019/06/20 06:01
PMCR- 2019/06/12
CRDT- 2019/06/20 06:00
PHST- 2019/05/21 00:00 [received]
PHST- 2019/06/06 00:00 [revised]
PHST- 2019/06/10 00:00 [accepted]
PHST- 2019/06/20 06:00 [entrez]
PHST- 2019/06/20 06:00 [pubmed]
PHST- 2019/06/20 06:01 [medline]
PHST- 2019/06/12 00:00 [pmc-release]
AID - diagnostics9020059 [pii]
AID - diagnostics-09-00059 [pii]
AID - 10.3390/diagnostics9020059 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2019 Jun 12;9(2):59. doi: 10.3390/diagnostics9020059.